


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A compound represented by the formula:




wherein R is  $C(O)-(CH_2)_m-X-R_1$ , wherein m is 0-10, X is a covalent bond, and  $R_1$  is optionally substituted, ~~unsaturated or partially saturated, 6-membered heterocycle pyridin-3-yl or optionally substituted thymine-1-yl.~~

2-7 (canceled)

8. (previously presented) The compound of claim 1, wherein m is 0 to 3.

9-12 (canceled)

13. (previously presented) A compound represented by the formula:



wherein R is  $C(O)-(CH_2)_m-X-R_1$ , wherein m is 0-3, X is a covalent bond, and  $R_1$  is 5-nitrofur-2-yl.

Claims 14-21 (canceled)

22. (previously presented) A therapeutically effective amount of the compound of claim 1 in combination with a pharmaceutically-acceptable excipient to form a pharmaceutical composition.

23. (original) The pharmaceutical composition of claim 22, which is in the form of a liposomal composition.

24. (previously presented) A method for treating breast cancer in a patient, which method comprises administering a therapeutically effective amount of a compound of claim 1 to the patient.

25-56 (canceled)

57. (previously presented) A therapeutically effective amount of the compound of claim 13 in combination with a pharmaceutically-acceptable excipient to form a pharmaceutical composition.

58. (previously presented) The pharmaceutical composition of claim 57, which is in the form of a liposomal composition.

59. (previously presented) A method for treating breast cancer in a patient, which method comprises administering a therapeutically effective amount of a compound of claim 13 to the patient.